Compounds and their use for reducing uric acid levels

A compound selected from the group consisting of

• a) compounds having a structure represented by Formula (II):
• wherein
• W is O, Y is selected from OH and N(R2)2, X is selected from O, S, and NR2;
• A is phenyl, heteroaryl, C5-C10 branched or unbranched cycloalkyl, C6-C10 bicycloalkyl or C5-C10 spirocycloalkyl;
• each Z is independently present or absent and, if present, is independently selected from one or more halogen atoms, —CN, —CF3, —OCF3, —OCHF2, —OR2, —C(O)R2, SR2, —S(O)gR3 where g is 1 or 2, —N(R2)2, —NO2, —CO2R2, —OCO2R3, OC(O)R2, —CON(R2)2, —NR2C(O)R2, —SO2N(R2)2, —NR2SO2R3, NR2SO2N(R2)2 or -NR2C(O)N(R2)2, —C(O)NHOR2, alkyl, aryl, alkenyl, alkynyl and cycloalkyl;
• wherein each R1 is C1-C8 branched or unbranched alkyl, optionally substituted with Z;
• wherein each R2 is H;
• wherein each R3 is independently alkyl or aryl, optionally substituted with one or more halogen atoms or OR2;
• and
• wherein a, b, c, d, and e are each independently carbon or nitrogen, or four of a, b, c, d, and e are each independently carbon or nitrogen and one of a, b, c, d, and e is O, with the proviso that at least three of a, b, c, d and e are nitrogen, and Z is not connected directly to nitrogen or oxygen;
• and
• b) tautomers of any of the foregoing compounds.